Evidence map›Paper›PMID 26585332›Full record

ReviewEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2016

Cancer stem cells in laryngeal cancer: what we know.

A Greco, Maria Ida Rizzo, A De Virgilio, A Gallo, M Fusconi, G Pagliuca, S Martellucci, R Turchetta, M De Vincentiis

Abstract readReview
PubMed Publisher
In one paragraph

Review in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.1field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Identification of prognostic immune genes in laryngeal cancer.The Journal of international medical research · 2020
    Article
  8. Article
  9. Article
  10. Targeting cancer stem cell pathways for cancer therapy.Signal transduction and targeted therapy · 2020
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

A GrecoDepartment Organs of Sense, ENT Section, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
Maria Ida RizzoDepartment of Surgical Science, Advanced Technology in Surgery, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy. mariaidarizzo@gmail.com.
A De VirgilioDepartment of Surgical Science, Advanced Technology in Surgery, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
A GalloDepartment Organs of Sense, ENT Section, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
M FusconiDepartment Organs of Sense, ENT Section, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
G PagliucaDepartment Organs of Sense, ENT Section, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
S MartellucciDepartment Organs of Sense, ENT Section, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
R TurchettaDepartment Organs of Sense, ENT Section, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
M De VincentiisDepartment Organs of Sense, ENT Section, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
Policlinico Umberto I · ITSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer stem cells (CSCs) are a group of cells with eternal life or infinite self-renewal ability, which have high migrating, infiltrative, and metastatic abilities. Though CSCs only account for a small proportion in tumors, the high resistance to traditional therapy exempts them from therapy killing and thus they can reconstruct tumors. Previous studies found that heterogeneity of cancer cells extensively exists in head and neck cancers. Our current knowledge, about CSCs in the laryngeal cancer (LC), largely depends on head and neck studies. Given the lack of systematic data about CSCs in LC, we propose a review of the literature, reporting the evidences of CSCs in tumorigenesis of LC, with the purpose to provide new insights into the prevention and/or treatment of laryngeal carcinoma.

Indexed as

Neoplastic Stem CellsAC133 AntigenAldehyde DehydrogenaseAnimalsCarcinogenesisCell HypoxiaCell Transformation, NeoplasticEpithelial-Mesenchymal TransitionFibroblastsHead and Neck NeoplasmsHumansHyaluronan ReceptorsLaryngeal NeoplasmsTumor MicroenvironmentAC133 AntigenAldehyde DehydrogenaseHyaluronan ReceptorsCancer stem cellsEpithelial-to-mesenchymal transitionLaryngeal carcinomaSide populationStemness markers

Identifiers

PMID26585332
OpenAlexW2175885710

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.